ethyl 3-(3-cyano-4-hydroxyphenyl)propanoate | 246219-37-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 3-(3-cyano-4-hydroxyphenyl)propanoate
• CAS: 246219-37-4
• 化学式: C₁₂H₁₃NO₃
• 分子量: 219.24
• InChiKey: ZLBUNOKKJNRTHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  70.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3-(3-cyano-4-hydroxyphenyl)propanoate 、 (S)-缩水甘油 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 23.0h， 以57%的产率得到ethyl 3-(3-cyano-4-{[(2R)-2-oxiranylmethyl]oxy}phenyl)propanoate
  参考文献：
  名称：

  Antagonists of the Calcium Receptor. 2. Amino Alcohol-Based Parathyroid Hormone Secretagogues

  摘要：

  When administered as a single agent to rats the previously reported calcium receptor antagonist 3 elicited a sustained elevation of plasma PTH resulting in no increase in overall bone mineral density. The lack of a bone building effect for analogue 3 was attributed to the large volume of distribution (V-dss(rat) = 11 L/kg) producing a protracted plasma PTH profile. Incorporation of a carboxylic acid functionality into the amino alcohol template led to the identification of 12 with a lower volume of distribution (V-dss(12) = 1.18 L/kg) and a shorter half-life. The zwitterionic nature of antagonist 12 necessitated the utility of an ester prodrug approach to increase overall permeability. Antagonist 12 elicited a rapid and transient increase in circulating levels of PTH following oral dosing of the ester prodrug 11 in the dog. The magnitude and duration of the increases in plasma levels of PTH would be expected to stimulate new bone formation.

  DOI：

  10.1021/jm900563e
• 作为产物：
  描述：

  copper(l) cyanide 、 3-(3-溴-4-羟基苯基)丙酸乙酯 以 N-甲基吡咯烷酮 为溶剂， 反应 2.0h， 以73.8%的产率得到ethyl 3-(3-cyano-4-hydroxyphenyl)propanoate
  参考文献：
  名称：

  Antagonists of the Calcium Receptor. 2. Amino Alcohol-Based Parathyroid Hormone Secretagogues

  摘要：

  When administered as a single agent to rats the previously reported calcium receptor antagonist 3 elicited a sustained elevation of plasma PTH resulting in no increase in overall bone mineral density. The lack of a bone building effect for analogue 3 was attributed to the large volume of distribution (V-dss(rat) = 11 L/kg) producing a protracted plasma PTH profile. Incorporation of a carboxylic acid functionality into the amino alcohol template led to the identification of 12 with a lower volume of distribution (V-dss(12) = 1.18 L/kg) and a shorter half-life. The zwitterionic nature of antagonist 12 necessitated the utility of an ester prodrug approach to increase overall permeability. Antagonist 12 elicited a rapid and transient increase in circulating levels of PTH following oral dosing of the ester prodrug 11 in the dog. The magnitude and duration of the increases in plasma levels of PTH would be expected to stimulate new bone formation.

  DOI：

  10.1021/jm900563e

文献信息

• CALCILYTIC COMPOUNDS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1070048A1

  公开（公告）日：2001-01-24
• EP1070048A4
  申请人：——

  公开号：EP1070048A4

  公开（公告）日：2001-11-07
• US6395919B1
  申请人：——

  公开号：US6395919B1

  公开（公告）日：2002-05-28
• [EN] CALCILYTIC COMPOUNDS<br/>[FR] COMPOSES CALCILYTIQUES
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：WO1999051569A1

  公开（公告）日：1999-10-14

  (EN) Novel calcilytic compounds, pharmaceutical compositions containing said compounds and their use as calcium receptor antagonists.(FR) La présente invention concerne de nouveaux composés calcilytiques, des compositions pharmaceutiques renfermant lesdits composés ainsi que leur utilisation comme antagonistes des récepteurs du calcium.
• Antagonists of the Calcium Receptor. 2. Amino Alcohol-Based Parathyroid Hormone Secretagogues
  作者：Robert W. Marquis、Amparo M. Lago、James F. Callahan、Attiq Rahman、Xiaoyang Dong、George B. Stroup、Sandra Hoffman、Maxine Gowen、Eric G. DelMar、Bradford C. Van Wagenen、Sarah Logan、Scott Shimizu、John Fox、Edward F. Nemeth、Theresa Roethke、Brian R. Smith、Keith W. Ward、Pradip Bhatnagar

  DOI：10.1021/jm900563e

  日期：2009.11.12

  When administered as a single agent to rats the previously reported calcium receptor antagonist 3 elicited a sustained elevation of plasma PTH resulting in no increase in overall bone mineral density. The lack of a bone building effect for analogue 3 was attributed to the large volume of distribution (V-dss(rat) = 11 L/kg) producing a protracted plasma PTH profile. Incorporation of a carboxylic acid functionality into the amino alcohol template led to the identification of 12 with a lower volume of distribution (V-dss(12) = 1.18 L/kg) and a shorter half-life. The zwitterionic nature of antagonist 12 necessitated the utility of an ester prodrug approach to increase overall permeability. Antagonist 12 elicited a rapid and transient increase in circulating levels of PTH following oral dosing of the ester prodrug 11 in the dog. The magnitude and duration of the increases in plasma levels of PTH would be expected to stimulate new bone formation.